TELA · TELA Bio, Inc.
$0.70
+0.05 (+7.69%)
At close · Aug 28
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions and events raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued.”View the 10-Q filed Aug 11, 2026
Market Cap
$31.43M
Shares
44.89M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$80.28M
+15.8%
FY2025
Net Income
-$38.83M
-2.6%
FY2025
Gross Margin
67.69%
+0.6pp
FY2025
Operating Margin
-42.05%
+7.2pp
FY2025
Diluted EPS
-$0.83
+37.6%
FY2025
Operating Cash Flow
-$28.22M
+32.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $79.91M | $80.28MG | $69.3MG | $58.45MG | $41.42MG | $29.46M | $18.21M | $15.45M | $8.27M | $4.25M | |
| $54.19M | $54.34M | $46.49M | $40.11M | $27.04M | $18.81M | $11.23M | $9.27M | $2.94M | $2.53M | |
| — | 67.69% | 67.08% | 68.62% | 65.3% | 63.85% | 61.68% | 60.03% | 35.56% | 59.65% | |
| $9.54M | $9.22M | $8.81M | $9.62M | $8.94M | $6.74M | $4.26M | $4.15M | $4.34M | $5.79M | |
| $62.7M | $63.18M | $64.65M | $59.68M | $43.25M | $29.06M | $22.11M | $18.06M | $13.65M | $8.71M | |
| $15.96M | $15.69M | $14.72M | $14.89M | $13.86M | $12.46M | $10.14M | $6.22M | $4.9M | $4.96M | |
| $88.2M | $88.1M | $88.18M | $84.19M | $66.05M | $48.26M | $36.51M | $28.43M | $20.72M | $19.46M | |
| -$34.01M | -$33.76M | -$34.12M | -$44.08M | -$39.01M | -$29.45M | -$25.28M | -$19.16M | -$17.78M | -$16.92M | |
| — | -42.05% | -49.23% | -75.4% | -94.18% | -99.96% | -138.77% | -124.06% | -214.91% | -398.68% | |
| $6.97M | $5.25M | $5.29M | $5.22M | $4.05M | $3.6M | $3.56M | $3.61M | $1.8M | $4.56M | |
| -$6.9M | -$4.85M | -$3.87M | -$2.59M | -$5.29M | -$3.83M | -$3.52M | -$3.26M | -$3.31M | -$4.41M | |
| -$40.91M | -$38.6M | -$37.99M | -$46.66M | -$44.3M | — | — | — | — | — | |
| $265K | $230K | -$144K | — | — | — | — | — | — | — | |
| -$41.18M | -$38.83M | -$37.84M | -$46.66M | -$44.3M | -$33.28M | -$28.79M | -$22.43M | -$21.09M | -$21.33M | |
| — | -48.37% | -54.6% | -79.83% | -106.95% | -112.94% | -158.1% | -145.18% | -254.92% | -502.57% | |
| — | — | — | — | — | -$33.28M | -$28.79M | -$30.21M | -$29.92M | -$27.23M | |
| -$41.19M | -$38.83M | -$37.84M | -$46.72M | -$44.09M | -$33.26M | -$28.85M | -$22.44M | -$21.09M | -$21.33M | |
| USD/shares | -$0.77 | -$0.83 | -$1.33 | -$2.04 | -$2.72 | -$2.30 | -$2.23 | -$17.10 | — | — |
| USD/shares | -$0.77 | -$0.83 | -$1.33 | -$2.04 | -$2.72 | -$2.30 | -$2.23 | -$17.10 | — | — |
| shares | — | 46.95M | 28.53M | 22.87M | 16.27M | 14.47M | 12.93M | 1.77M | 294.99K | 291.96K |
| shares | — | 46.95M | 28.53M | 22.87M | 16.27M | 14.47M | 12.93M | 1.77M | 294.99K | 291.96K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.47×
Peer median 1.54×
EV/EBIT
—
Peer median 19.54×
P/E (TTM)
—
Peer median 26.44×
Peer medians compare against the 68 similar-size Medical Devices companies (of 144 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Single Reportable Segment | $80,275,000 | $69,300,000 | $58,453,000 | $41,418,000 |
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Non Us | $12,100,000 | $10,300,000 | $6,100,000 | $3,200,000 |
Key facts
CIK
1561921
CUSIP
872381108
13F (30d)
40 filings
38 filers
Visit website
Investor relations